MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.

摘要: Abstract The purpose of this investigation was to compare the sensitivity and safety high dose gadoteridol (ProHance) with routine gadopentetate dimeglumine (Magnevist) in detection intracranial metastases on magnetic resonance imaging (MRI) when a solitary lesion detected contrast-enhanced cranial computed tomography (CT). Four patients, each metastasis demonstrated CT were studied prospectively both 0.3 mmol/kg 0.1 dimeglumine. Images acquired before immediately following contrast administration. Both MR studies performed between two six days other within 1 wk CT. Scan parameters injection rates identical occasions. Patient monitoring for study included physical examination, vital signs laboratory tests at several pre-determined times. Eighteen total MRI compared four Seven visualized unenhanced images, nine scans using dimeglumine, all eighteen gadoteridol. Additional lesions seen images patients. No adverse events attributable media occurred. significant changes or values